Wall Street Zen Downgrades CG Oncology to Sell Rating

Analysts cite concerns over the company's future performance and growth prospects.

Mar. 28, 2026 at 5:39am

Got story updates? Submit your updates here. ›

Wall Street Zen, a prominent investment research firm, has downgraded CG Oncology (NASDAQ:CGON) from a 'hold' rating to a 'sell' rating in a new research report. The downgrade comes as analysts express doubts about the company's ability to maintain its recent growth trajectory and profitability.

Why it matters

CG Oncology is a clinical-stage biopharmaceutical company focused on developing novel antibody-based immunotherapies for solid tumor cancers. The company's stock performance and analyst ratings are closely watched by investors in the highly competitive oncology drug development space.

The details

In their report, Wall Street Zen analysts cited concerns over CG Oncology's pipeline progress, upcoming clinical trial results, and the company's ability to effectively compete with larger pharmaceutical players. The downgrade follows a series of positive analyst notes and price target increases from other firms over the past several months.

  • Wall Street Zen issued the downgrade report on Saturday, March 28, 2026.
  • CG Oncology's stock price has declined by 3.1% in Friday trading.

The players

Wall Street Zen

A prominent investment research firm that provides equity analysis and ratings for public companies.

CG Oncology

A clinical-stage biopharmaceutical company focused on developing novel antibody-based immunotherapies for solid tumor cancers.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching CG Oncology's upcoming clinical trial results and pipeline updates to see if the company can address the concerns raised by Wall Street Zen and regain analyst confidence.

The takeaway

The downgrade of CG Oncology by Wall Street Zen highlights the challenges faced by clinical-stage biotech companies in the highly competitive oncology drug development landscape, where maintaining investor and analyst support is crucial for long-term success.